A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Abroad (travel likely)RecruitingPHASE1
Conditions
Gastrointestinal Stromal Tumors · Small-cell Lung Cancer · Adenoid Cystic Carcinoma · Uveal Melanoma · Neuroendocrine Tumors · Chromophobe Renal Cell Carcinoma · Clear Cell Renal Cell Carcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of Michigan Hospitals, Ann Arbor, Michigan, United States
Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Contact: Study coordinator (Ankit Mangla, MD)Oregon Health & Science University, Portland, Oregon, United States
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
NEXT Virginia, Fairfax, Virginia, United States
Study leads
Sunil Sharma, MD
Principal Investigator
Novelty Nobility